Dual-Balloon Catheter for Benign Prostatic Hypertrophy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for benign prostatic hypertrophy, such as TURP and open resection, often result in complications like retrograde ejaculation and erection problems, and there is a need for a simpler, repeatable outpatient procedure that can effectively treat the condition.
Innovation Solution
A urethral catheter with two balloons, one for positioning and another for mechanical action and drug release, allowing for both pharmacological and mechanical treatment by delivering drugs like taxol or its derivatives directly to the urethral canal and dilating the urethral canal for localized treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If TURP endoscopic surgical therapy or open resection is used to treat benign prostatic hypertrophy, then the obstruction of the urethral channel is removed, but retrograde ejaculation occurs in 100% of TURP cases and erection problems may occur in open intervention
Solution Approach 1:
The treatment is divided into two independent components: mechanical dilation of the urethral channel and pharmacological treatment with chemotherapy drugs. This segmentation allows the mechanical function to be achieved while the pharmacological component prevents the harmful effects of tissue damage that cause retrograde ejaculation and erection problems.
Solution Approach 2:
The traditional mechanical surgical resection system is replaced with a minimally invasive balloon dilation system combined with pharmacological action. The balloon provides gentle mechanical expansion without the tissue cutting and damage inherent in TURP or open resection, thereby avoiding the harmful side effects.
2Reliability
If traditional surgical treatments are performed, then effective treatment of benign prostatic hypertrophy is achieved, but the procedures are complex and require hospitalization
Solution Approach 1:
The treatment system is segmented into a simple catheter-based delivery device and a separate drug application system. This allows the complex pharmacological treatment to be delivered through a simple outpatient procedure, separating the complexity of the treatment protocol from the procedural invasiveness.
Solution Approach 2:
The chemotherapy drugs are applied topically to the prostate tissue through the balloon, allowing the tissue to self-absorb the medication without requiring complex delivery systems or prolonged hospitalization. The body's natural processes handle drug distribution and elimination.
3Object-affected harmful factors
If chemotherapy drugs are applied to treat prostate hyperplasia, then localized treatment with minimal systemic side effects is achieved, but the drugs must be delivered directly to the target tissue
Solution Approach 1:
The balloon acts as an intermediary device that facilitates direct contact between the chemotherapy drugs and the prostate tissue. The balloon is positioned within the urethral channel adjacent to the prostate, serving as a mediator that enables localized drug delivery without requiring complex surgical access procedures.
Solution Approach 2:
The balloon provides a flexible, conformable surface that can be positioned against the prostate tissue, ensuring intimate contact between the drug-coated balloon surface and the target tissue. This flexible interface simplifies the delivery process while maximizing localized drug exposure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables effective, repeatable, and outpatient treatment of benign prostatic hypertrophy with minimal systemic side effects, using chemotherapy drugs that penetrate the prostate to reduce growth, without the need for radiological equipment, and with a service life of at least three years.
Implementation Method 1
mechanical expansion of the canal itself
Implementation Method 2
chemotherapy drugs that penetrate the prostate to reduce growth
Data Source
AI summary
This application is directed to an at least two-way catheter comprising: a first balloon (110, 210) near the end of the catheter; a second balloon (120, 220) at a distance from the first balloon between 0 mm and 6 mm; wherein the first (140, 240) and second tube (150, 250) are coaxial, and the first tube is internal to the second tube, and wherein a drug is present on the surface of the second balloon, wherein the drug is selected from the group consisting of paclitaxel and derivatives thereof, rapamicyn and derivatives thereof, and mixtures thereof.